Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of <i>Candida auris</i> Infections

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of <i>Candida auris</i> Infections

<i>Candida auris</i> is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to <i>C. auris</i> are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment....

Full description

Bibliographic Details
Main Authors: Mahmoud Ghannoum, Maiken Cavling Arendrup, Vishnu P. Chaturvedi, Shawn R. Lockhart, Thomas S. McCormick, Sudha Chaturvedi, Elizabeth L. Berkow, Deven Juneja, Bansidhar Tarai, Nkechi Azie, David Angulo, Thomas J. Walsh
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Antibiotics
Subjects:
antifungal
ibrexafungerp
<i>Candida</i> <i>auris</i>
resistance
Online Access:https://www.mdpi.com/2079-6382/9/9/539

Internet

https://www.mdpi.com/2079-6382/9/9/539

Similar Items